Tandem Mobi (pump)

The Tandem Mobi is, by the manufacturer's claim, the world's smallest durable automated insulin delivery system — a miniature pump less than half the size of Tandem's own t:slim X2, small enough to slip into the coin pocket of a pair of jeans.¹² It is a tubed pump, not a patch, but it shrinks the tubed format dramatically: the small durable pump body connects to the body through a short, detachable infusion set, including a 5-inch tubing option made specifically for the Mobi, so you can briefly disconnect to shower or swim.²

Reservoir and wear. The Mobi uses a clear ~200-unit insulin cartridge, smaller than the t:slim X2's ~300-unit cartridge, which is the trade-off for its size.¹² The cartridge is paired with standard Tandem infusion sets, so the site/cannula is changed every two to three days like any conventional pump.² The pump body itself is durable and rechargeable by wireless (inductive) charging, and it is water-resistant to an IP28 rating (tested at 8 feet for 2 hours).³

Infusion set and occlusion detection. Because it is compatible with the full Tandem infusion-set range, users can mix and match cannula type, angle, and tubing length.²³ Like other Tandem pumps it includes occlusion (blockage) detection and alarms; as with any infusion-set pump, a kinked or bent cannula will not always trigger an alarm, so site rotation and monitoring still matter.⁴

Which CGMs and algorithms it works with. The Mobi is a closed commercial AID system. It integrates with the Dexcom G6 and Dexcom G7 continuous glucose monitors and runs Tandem's Control-IQ+ algorithm, which reads CGM values, predicts glucose 30 minutes ahead, and automatically adjusts insulin every five minutes.³⁵ It does not support Abbott's FreeStyle Libre on the Mobi, and it is not an open platform — there is no official DIY/open-source looping.⁶ The underlying Control-IQ algorithm is among the best-evidenced in the field: in the pivotal NEJM randomized trial it raised time in range from 61% to 71% versus an unchanged control group.⁷ Real-world data from more than 40,000 Control-IQ+ users (t:slim X2 and Mobi) show a median time in range around 71% with very low hypoglycemia.⁸ Tandem cites up to 79% daytime and 90% overnight time in range.¹

Phone bolusing. The Mobi's headline feature is that it is the only AID system fully controllable from a phone — you can bolus for meals directly from the app.³ iOS control launched at U.S. release in February 2024, and the FDA cleared the Android app on 10 November 2025 (Pixel 6-10, Galaxy S21-S25), with broad rollout in early 2026.²¹ A multifunction button on the pump delivers a bolus without the phone as a backup.²

Access and cost. As of mid-2026 the Mobi is available only in the United States, cleared for people aged 6 and older.² It is CE-marked for Europe but not yet commercially launched there; international rollout is expected from 2026 onward.¹ It is distributed through durable-medical-equipment channels like other Tandem pumps; exact out-of-pocket cost depends on insurance.

What's coming. Tandem is developing a tubeless version of the Mobi: the same pump body would slide into an adhesive patch (via a side-clip design) using a new 7-day SteadiSet infusion set, making it a first-of-its-kind hybrid that can be worn either tubed or tubeless.⁹ Tandem has signaled an FDA submission with clearance anticipated in 2026, which would directly address the Mobi's main weakness — that it is still, today, a tubed pump.⁹

References

1. Beyond Type 1. Tandem Mobi Receives FDA Clearance for Use with Android Smartphones. beyondtype1.org (2025). https://beyondtype1.org/fda-approval-tandem-mobi-android/ ↩ ↩² ↩³ ↩⁴ ↩⁵

2. Beyond Type 1. The Tandem Mobi is Now Available. beyondtype1.org (2024). https://beyondtype1.org/the-tandem-mobi-is-now-available/ ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸

3. Tandem Diabetes Care. Tandem Mobi Automated Insulin Delivery System. tandemdiabetes.com (accessed 2026). https://www.tandemdiabetes.com/products/insulin-pumps/tandem-mobi ↩ ↩² ↩³ ↩⁴

4. Sawyer A, Forlenza GP, Wadwa RP. An overview of the t:slim X2 and Mobi insulin pumps with Control-IQ technology: patient safety and device efficacy. Expert Review of Medical Devices (2025). doi:10.1080/17434440.2025.2585061. https://pubmed.ncbi.nlm.nih.gov/41175172/ ↩

5. Beyond Type 1. Tandem Mobi Pump and the Dexcom G7 CGM Are Now Connected. beyondtype1.org (2024). https://beyondtype1.org/tandem-mobi-dexcom-g7-integration/ ↩

6. Tandem Diabetes Care. CGM Sensor Compatibility. tandemdiabetes.com (accessed 2026). https://www.tandemdiabetes.com/support/cgm-compatibility ↩

7. Brown SA, Kovatchev BP, Raghinaru D, et al. Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. New England Journal of Medicine (2019). doi:10.1056/NEJMoa1907863. https://pubmed.ncbi.nlm.nih.gov/31618560/ ↩

8. Assadi KZ, D'Souza EW, Pinsker JE, Messer LH. First Use of Control-IQ+ Technology in Newly Indicated Populations. Diabetes Technology & Therapeutics (2026). doi:10.1177/15209156261456818. https://pubmed.ncbi.nlm.nih.gov/42267588/ ↩

9. Reuter E. Tandem to file tubeless insulin pump with FDA this quarter. MedTech Dive (2025). https://www.medtechdive.com/news/tandem-to-file-tubeless-insulin-pump-with-fda-this-quarter/819722/ ↩ ↩²